0      0

DNA's 39th Annual Convention On-Demand

GS231 - Studies in Clearance - Skyrizi in Moderate-to-Severe Plaque Psoriasis. Sponsored by AbbVie Inc

Apr 22, 2021 1:00pm ‐ Apr 22, 2021 2:00pm

Credits: None available.

Learning Objectives:
  • Align on the need to raise treatment standards for patients and psoriatic disease.
  • Reveiw the results from the UltlMMa-1, LIMMitless, and IMMvent trials.
  • Explore the outcomes of subanalyses of data on treatment switching.



Credits: None available.

You must be logged in and own this session in order to post comments.

Barbara A Bradley
5/14/21 1:44 pm

good job